SCHEMBL3292227

SCHEMBL3292227

NCCOCCCOCCN

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ODC1 P11926 1/20 0.37
NFKB1 P19838 1/20 0.33
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA3 P07451 2/20 0.31
CA4 P22748 2/20 0.31
CA6 P23280 2/20 0.31
CA5A P35218 2/20 0.31
CA7 P43166 2/20 0.31
CA9 Q16790 2/20 0.31
CA14 Q9ULX7 2/20 0.31
CA5B Q9Y2D0 2/20 0.31
TSHR P16473 2/20 0.31
DNM1 Q05193 1/20 0.31
LMNA P02545 1/20 0.31
BLM P54132 1/20 0.31
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12918856 1.00 ODC1 (0.37) ODC1NFKB1CA12CA1CA2
Hydrochloric Acid SCHEMBL23202615 0.96 ODC1 (0.35) ODC1NFKB1
SCHEMBL6051828 0.93 ODC1 (0.47) ODC1NFKB1CA12CA1CA2
SCHEMBL4001682 0.92 ODC1 (0.37) ODC1NFKB1CA12CA1CA2
SCHEMBL30050208 0.90 ODC1 (0.38) ODC1
SCHEMBL17110675 0.90 ODC1 (0.45) ODC1NFKB1CA12CA1CA2
SCHEMBL3996449 0.89 CA1 (0.38) ODC1NFKB1CA12CA1CA2
SCHEMBL18902842 0.89 CA1 (0.38) ODC1NFKB1CA12CA1CA2
SCHEMBL3998325 0.89 CA1 (0.38) ODC1NFKB1CA12CA1CA2
SCHEMBL16353341 0.89 MEN1 (0.36) ODC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479840-B2 HMG-CoA reductase degradation inducing compound UPPTHERA INC. (KR) 2025-11-25 US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20250163006-A1 New Coolants, and Preparations Containing Same SYMRISE AG (DE) 2025-05-22 US disclosed
CN-119569587-A Preparation method of alkoxy diethyl amine 上海彩迩文生化科技有限公司 2025-03-07 CN disclosed
EP-3663366-B1 USE OF PHYSIOLOGICAL COOLING INGREDIENTS AND AGENTS CONTAINING SUCH ACTIVE INGREDIENTS SYMRISE AG (DE) 2025-01-08 EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 US disclosed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP disclosed
EP-1200507-B1 ZWITTERIONIC POLYETHERPOLYAMINES AND A PROCESS FOR THEIR PRODUCTION BASF AG (DE) 2003-11-19 EP disclosed
US-20020165111-A1 LAUNDRY DETERGENT COMPOSITIONS COMPRISING ZWITTERIONIC POLYAMINES AND XYLOGLUCANASE PROCTER & GAMBLE COMPANY, THE 2002-11-07 US disclosed
US-6472359-B1 Laundry detergent compositions comprising zwitterionic polyamines and xyloglucanase THE PROCTER & GAMBLE COMPANY 2002-10-29 US disclosed
EP-1200507-A1 ZWITTERIONIC POLYETHERPOLYAMINES AND A PROCESS FOR THEIR PRODUCTION BASF AKTIENGESELLSCHAFT (DE) 2002-05-02 EP disclosed
EP-1196525-A1 LAUNDRY DETERGENT COMPOSITIONS COMPRISING POLYAMINES AND MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 2002-04-17 EP disclosed
EP-1196524-A1 LAUNDRY DETERGENT COMPOSITIONS COMPRISING ZWITTERIONIC POLYAMINES AND MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 2002-04-17 EP disclosed
WO-2001005872-A1 ZWITTERIONIC POLYETHERPOLYAMINES AND A PROCESS FOR THEIR PRODUCTION BASF AKTIENGESELLSCHAFT (DE) 2001-01-25 WO disclosed
WO-2001005923-A1 LAUNDRY DETERGENT COMPOSITIONS COMPRISING ZWITTERIONIC POLYAMINES AND MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 2001-01-25 WO disclosed
WO-2001005924-A1 LAUNDRY DETERGENT COMPOSITIONS COMPRISING POLYAMINES AND MID-CHAIN BRANCHED SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 2001-01-25 WO disclosed
EP-0393549-A2 Process for preparing linear polyamids containing ether linkages in their polymeric chain BASF Aktiengesellschaft (DE) 1990-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ODC1 3109/4885NFKB1 126/4885CA12 4583/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ODC1 3109/4885NFKB1 126/4885CA12 4583/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ODC1 3109/4885NFKB1 126/4885CA12 4583/4885
US-20250163006-A1 New Coolants, and Preparations Containing Same TTR, TAS2R5, TAS2R50 ODC1 3461/4885NFKB1 3887/4885CA12 744/4885
US-12479840-B2 HMG-CoA reductase degradation inducing compound HMGCR, HMGB2, LDLR ODC1 2645/4885NFKB1 677/4885CA12 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.